NEW YORK – Thermo Fisher Scientific saw its business grow sharply in the second quarter, even as many of its research customers had their operations curtailed or shut down. The company's revenue growth was propelled by demand for products and services related to COVID-19, including diagnostic testing, personal protective equipment, and vaccine and therapy development.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.